188 related articles for article (PubMed ID: 32770382)
1. Anticancer effects of the PLK4 inhibitors CFI-400945 and centrinone in Ewing's sarcoma cells.
Kerschner-Morales SL; Kühne M; Becker S; Beck JF; Sonnemann J
J Cancer Res Clin Oncol; 2020 Nov; 146(11):2871-2883. PubMed ID: 32770382
[TBL] [Abstract][Full Text] [Related]
2. Synergistic anticancer activity of combined ATR and ribonucleotide reductase inhibition in Ewing's sarcoma cells.
Sturm MJ; Henao-Restrepo JA; Becker S; Proquitté H; Beck JF; Sonnemann J
J Cancer Res Clin Oncol; 2023 Sep; 149(11):8605-8617. PubMed ID: 37097390
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing's sarcoma cells.
Sonnemann J; Dreyer L; Hartwig M; Palani CD; Hong le TT; Klier U; Bröker B; Völker U; Beck JF
J Cancer Res Clin Oncol; 2007 Nov; 133(11):847-58. PubMed ID: 17486365
[TBL] [Abstract][Full Text] [Related]
4. RETRA exerts anticancer activity in Ewing's sarcoma cells independent of their TP53 status.
Sonnemann J; Grauel D; Blümel L; Hentschel J; Marx C; Blumrich A; Focke K; Becker S; Wittig S; Schinkel S; Krämer OH; Beck JF
Eur J Cancer; 2015 May; 51(7):841-51. PubMed ID: 25801700
[TBL] [Abstract][Full Text] [Related]
5. Polo-like kinase 4 inhibition produces polyploidy and apoptotic death of lung cancers.
Kawakami M; Mustachio LM; Zheng L; Chen Y; Rodriguez-Canales J; Mino B; Kurie JM; Roszik J; Villalobos PA; Thu KL; Silvester J; Cescon DW; Wistuba II; Mak TW; Liu X; Dmitrovsky E
Proc Natl Acad Sci U S A; 2018 Feb; 115(8):1913-1918. PubMed ID: 29434041
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Polo-like kinase 4 induces mitotic defects and DNA damage in diffuse large B-cell lymphoma.
Zhao Y; Yang J; Liu J; Cai Y; Han Y; Hu S; Ren S; Zhou X; Wang X
Cell Death Dis; 2021 Jun; 12(7):640. PubMed ID: 34162828
[TBL] [Abstract][Full Text] [Related]
7. Reverse chemomodulatory effects of the SIRT1 activators resveratrol and SRT1720 in Ewing's sarcoma cells: resveratrol suppresses and SRT1720 enhances etoposide- and vincristine-induced anticancer activity.
Sonnemann J; Kahl M; Siranjeevi PM; Blumrich A; Blümel L; Becker S; Wittig S; Winkler R; Krämer OH; Beck JF
J Cancer Res Clin Oncol; 2016 Jan; 142(1):17-26. PubMed ID: 26055805
[TBL] [Abstract][Full Text] [Related]
8. Potential use of imatinib in Ewing's Sarcoma: evidence for in vitro and in vivo activity.
Merchant MS; Woo CW; Mackall CL; Thiele CJ
J Natl Cancer Inst; 2002 Nov; 94(22):1673-9. PubMed ID: 12441322
[TBL] [Abstract][Full Text] [Related]
9. The sirtuin 1/2 inhibitor tenovin-1 induces a nonlinear apoptosis-inducing factor-dependent cell death in a p53 null Ewing's sarcoma cell line.
Marx C; Marx-Blümel L; Lindig N; Thierbach R; Hoelzer D; Becker S; Wittig S; Lehmann R; Slevogt H; Heinzel T; Wang ZQ; Beck JF; Sonnemann J
Invest New Drugs; 2018 Jun; 36(3):396-406. PubMed ID: 29150734
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of SOX2 induces cell apoptosis and G1/S arrest in Ewing's sarcoma through the PI3K/Akt pathway.
Ren C; Ren T; Yang K; Wang S; Bao X; Zhang F; Guo W
J Exp Clin Cancer Res; 2016 Mar; 35():44. PubMed ID: 26969300
[TBL] [Abstract][Full Text] [Related]
11. Preclinical studies of treosulfan demonstrate potent activity in Ewing's sarcoma.
Werner S; Mendoza A; Hilger RA; Erlacher M; Reichardt W; Lissat A; Konanz C; Uhl M; Niemeyer CM; Khanna C; Kontny U
Cancer Chemother Pharmacol; 2008 Jun; 62(1):19-31. PubMed ID: 17823799
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Protein Kinase Inhibitors with PLK4 Cross-Over Potential in a Pre-Clinical Model of Cancer.
Suri A; Bailey AW; Tavares MT; Gunosewoyo H; Dyer CP; Grupenmacher AT; Piper DR; Horton RA; Tomita T; Kozikowski AP; Roy SM; Sredni ST
Int J Mol Sci; 2019 Apr; 20(9):. PubMed ID: 31035676
[TBL] [Abstract][Full Text] [Related]
13. Use of the Polo-like kinase 4 (PLK4) inhibitor centrinone to investigate intracellular signalling networks using SILAC-based phosphoproteomics.
Byrne DP; Clarke CJ; Brownridge PJ; Kalyuzhnyy A; Perkins S; Campbell A; Mason D; Jones AR; Eyers PA; Eyers CE
Biochem J; 2020 Jul; 477(13):2451-2475. PubMed ID: 32501498
[TBL] [Abstract][Full Text] [Related]
14. Interferon-gamma sensitizes resistant Ewing's sarcoma cells to tumor necrosis factor apoptosis-inducing ligand-induced apoptosis by up-regulation of caspase-8 without altering chemosensitivity.
Lissat A; Vraetz T; Tsokos M; Klein R; Braun M; Koutelia N; Fisch P; Romero ME; Long L; Noellke P; Mackall CL; Niemeyer CM; Kontny U
Am J Pathol; 2007 Jun; 170(6):1917-30. PubMed ID: 17525260
[TBL] [Abstract][Full Text] [Related]
15. Apoptotic responsiveness of the Ewing's sarcoma family of tumours to tumour necrosis factor-related apoptosis-inducing ligand (TRAIL).
Van Valen F; Fulda S; Truckenbrod B; Eckervogt V; Sonnemann J; Hillmann A; Rödl R; Hoffmann C; Winkelmann W; Schäfer L; Dockhorn-Dworniczak B; Wessel T; Boos J; Debatin KM; Jürgens H
Int J Cancer; 2000 Oct; 88(2):252-9. PubMed ID: 11004677
[TBL] [Abstract][Full Text] [Related]
16. Synergistic induction of apoptosis by a polo-like kinase 1 inhibitor and microtubule-interfering drugs in Ewing sarcoma cells.
Weiß LM; Hugle M; Romero S; Fulda S
Int J Cancer; 2016 Jan; 138(2):497-506. PubMed ID: 26260582
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of Ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells.
Scotlandi K; Perdichizzi S; Manara MC; Serra M; Benini S; Cerisano V; Strammiello R; Mercuri M; Reverter-Branchat G; Faircloth G; D'Incalci M; Picci P
Clin Cancer Res; 2002 Dec; 8(12):3893-903. PubMed ID: 12473605
[TBL] [Abstract][Full Text] [Related]
18. Activity of the novel polo-like kinase 4 inhibitor CFI-400945 in pancreatic cancer patient-derived xenografts.
Lohse I; Mason J; Cao PM; Pintilie M; Bray M; Hedley DW
Oncotarget; 2017 Jan; 8(2):3064-3071. PubMed ID: 27902970
[TBL] [Abstract][Full Text] [Related]
19. Arsenic trioxide inhibits Ewing's sarcoma cell invasiveness by targeting p38(MAPK) and c-Jun N-terminal kinase.
Zhang S; Guo W; Ren TT; Lu XC; Tang GQ; Zhao FL
Anticancer Drugs; 2012 Jan; 23(1):108-18. PubMed ID: 21946058
[TBL] [Abstract][Full Text] [Related]
20. Preclinical evidence that use of TRAIL in Ewing's sarcoma and osteosarcoma therapy inhibits tumor growth, prevents osteolysis, and increases animal survival.
Picarda G; Lamoureux F; Geffroy L; Delepine P; Montier T; Laud K; Tirode F; Delattre O; Heymann D; Rédini F
Clin Cancer Res; 2010 Apr; 16(8):2363-74. PubMed ID: 20371692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
